Work

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors

Year: 2009

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2009.27.15_suppl.3502

Authors: P. LoRusso, B. Markman, J. Tabernero, R. Shazer, L. Nguyen, E. Heath, A. Patnaik, K. Papadopoulos

Institutions: Exelixis (United States), The Barbara Ann Karmanos Cancer Institute, South Texas Accelerated Research Therapeutics

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2286779516

Cites:

Cited by: 39

Related to: 10